QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kaushik, P. Articles by Kaushik, R. Search for Related Content PubMed PubMed Citation Articles by Kaushik, P. Articles by Kaushik, R.

Acute Onset of Severe Dilated Cardiomyopathy During Bromocriptine Therapy

Staff Physician, Department of Internal Medicine, Hospital Medicine Group, Baton Rouge General Hospital, Baton Rouge, LA

Sundararama R Vatsavai, MD

Staff Physician, Department of Internal Medicine, Hospital Medicine Group, Baton Rouge General Hospital

Venkatramana R Banda, MD

Staff Physician, Department of Internal Medicine, Hospital Medicine Group, Baton Rouge General Hospital

Pramod K Sanghi, MD

Clinical Fellow, Division of Cardiology, Department of Internal Medicine, The University of Texas Medical Branch at Galveston, Galveston, TX

Masood Ahmad, MD

Professor, Division of Cardiology, Department of Internal Medicine, The University of Texas Medical Branch at Galveston

Richa Kaushik, MD

Clinical-Associate to the Hospital Medicine Group, Department of Internal Medicine, Baton Rouge General Hospital

Reprints: Prashant Kaushik MD, Hospital Medicine Group, PO Box 2511, Baton Rouge, LA 70821-2511, fax 225/387-7700, kaushikprashant{at}hotmail.com

OBJECTIVE: To report a case of severe dilated cardiomyopathy (DCMP) in a patient on bromocriptine therapy for a microprolactinoma.

CASE SUMMARY: A 31-year-old African American female, who had been receiving bromocriptine 5 mg orally daily for a microprolactinoma during the preceding month, developed severe DCMP. An echocardiogram showed a markedly dilated left ventricle with severe reduction in the left-ventricular ejection fraction in the absence of any other identifiable causes of DCMP such as a peripartum state, ethanol use, preceding systemic viral illness, chronic hypocalcemia, chronic hypophosphatemia, or chronic uncontrolled tachycardia. She improved substantially (both symptomatically and echocardiographically) after cessation of bromocriptine therapy and initiation of supportive treatment of congestive heart failure (CHF). She showed no recurrence of CHF at a follow-up visit 2 months after withdrawal of the supportive care. The patient was not rechallenged with bromocriptine due to the clinical/ethical gravity of this probable adverse effect.

DISCUSSION: Although cardiopulmonary adverse effects have been reported with the use of cabergoline (another dopamine agonist), to the best of our knowledge, this is the first case report of severe life-threatening DCMP associated with bromocriptine therapy. Causality assessment using the Naranjo probability scale revealed that the adverse drug event was probable.

CONCLUSIONS: Bromocriptine was probably associated with DCMP in a patient being treated for a microprolactinoma. Severe DCMP needs to be considered a potentially life-threatening but reversible adverse effect of bromocriptine therapy for microprolactinoma of the pituitary gland.

Key Words: bromocriptine, congestive heart failure, dilated cardiomyopathy

Published Online, June 1, 2004. www.theannals.com, DOI 10.1345/aph.1E075